AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33580585 — intervention group
Group type: COMPARATOR
Intervention: Supine position recruitment maneuver (Control)
Number of subjects: 84
Study 32590334 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with DCD
Number of subjects: 35
Study 32590334 — intervention group
Group type: COMPARATOR
Intervention: Typically-developing children
Number of subjects: 35
Study 35852694 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cream (steroid + synthetic pseudo‐ceramide), applied twice daily for 2 weeks
Number of subjects: 34
Study 35852694 — intervention group
Group type: COMPARATOR
Intervention: Control cream (steroid without pseudo‐ceramide), applied twice daily for 2 weeks
Number of subjects: 34
Study 32467099 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line docetaxel
Number of subjects: 120
Study 32467099 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line platinum-based chemotherapy
Number of subjects: 120
Study 36169608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope phosphorus-32 dressing combined with diprospan and mucopolysaccharide polysulphate cream
Number of subjects: 80
Study 36169608 — intervention group
Group type: COMPARATOR
Intervention: Diprospan combined with mucopolysaccharide polysulphate cream
Number of subjects: 80
Study 36169608 — intervention group
Group type: COMPARATOR
Intervention: Isotopic phosphorus-32 dressing combined with mucopolysaccharide polysulphate cream
Number of subjects: 80
Study 34521166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting sinus stent in one frontal sinus ostium (FSO)
Number of subjects: 31
Study 35305325 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette product placement in music videos (treatment group)
Number of subjects: 303
Study 35305325 — intervention group
Group type: COMPARATOR
Intervention: Control group (music videos with e-cigarette product placement and imagery digitally removed)
Number of subjects: 303
Study 34350385 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (350 mg intravenous on days 1 and 15 in 4‐wk cycles) combined with low‐dose cytarabine (LDAC; 20 mg subcutaneous, twice daily, days 1‐10)
Number of subjects: 666
Study 34350385 — intervention group
Group type: COMPARATOR
Intervention: LDAC plus placebo
Number of subjects: 666
Study 34350385 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (V) plus low‐dose cytarabine (LDAC)
Number of subjects: 666
Study 34350385 — intervention group
Group type: COMPARATOR
Intervention: LDAC plus placebo (P)
Number of subjects: 666
Study 35584873 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 90
Study 35584873 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 90
Study 34166373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ultrasound-guided hyaluronic acid injection
Number of subjects: 80
Study 34166373 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 80
Study 32746194 — intervention group
Group type: EXPERIMENTAL
Intervention: rSVD‐CFWI
Number of subjects: 0
Study 32746194 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD‐CFWI
Number of subjects: 0
Study 32746194 — intervention group
Group type: COMPARATOR
Intervention: BW‐CFWI
Number of subjects: 0
Study 32746194 — intervention group
Group type: COMPARATOR
Intervention: NCC‐BM
Number of subjects: 0
Study 32746194 — intervention group
Group type: EXPERIMENTAL
Intervention: rSVD‐CFWI and SVD‐CFWI
Number of subjects: 0
Study 35646743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufang Furong Effervescent Suppository
Number of subjects: 80
Study 35646743 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 80
Study 33796883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral calcaneal lengthening (LCL)
Number of subjects: 66
Study 33796883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtalar arthroereisis (SA)
Number of subjects: 66
Study 33796883 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 66
Study 34707777 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Number of subjects: 26
Study 34707777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33106174 — intervention group
Group type: EXPERIMENTAL
Intervention: non-invasive cervical VNS (nVNS) for 5 days in addition to standard treatment
Number of subjects: 150
Study 33106174 — intervention group
Group type: COMPARATOR
Intervention: standard treatment alone
Number of subjects: 150
Study 36317453 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal warming (42°C) using recirculated water through a multilumen, silicone tube (EnsoETM®; Attune Medical)
Number of subjects: 42
Study 36317453 — intervention group
Group type: COMPARATOR
Intervention: Luminal single-electrode esophageal temperature monitoring probe (LET)
Number of subjects: 42
Study 32236941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Number of subjects: 5087
Study 32236941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower haemoglobin threshold for transfusion
Number of subjects: 5087
Study 32236941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 5087
Study 33270254 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education program participation
Number of subjects: 310
Study 33270254 — intervention group
Group type: EXPERIMENTAL
Intervention: Online development evaluations
Number of subjects: 310
Study 33270254 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home sessions
Number of subjects: 310
Study 35899585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral nasal wall collapse (measured by LNWT area ratio)
Number of subjects: 24
Study 35899585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal obstruction)
Number of subjects: 24
Study 34115646 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Group Integrated Savings for Health Empowerment (GISHE) microfinance group
Number of subjects: 3609
Study 34115646 — intervention group
Group type: COMPARATOR
Intervention: Not participating in GISHE microfinance group
Number of subjects: 3609
Study 32215899 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400 mg/ml (group A)
Number of subjects: 253
Study 32215899 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol 300 mg/ml (group B)
Number of subjects: 253
Study 35103366 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 75
Study 35103366 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of tuberculin PPD
Number of subjects: 75
Study 35103366 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus intralesional injection of tuberculin PPD
Number of subjects: 75
Study 33429306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonword repetition tasks (3 tasks with varying complexity)
Number of subjects: 60
Study 33429306 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring based on phonemes produced correctly
Number of subjects: 60
Study 32580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 32580211 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 0
Study 36348363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 140
Study 36348363 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous integrated boost carbon ion radiotherapy
Number of subjects: 140
Study 34477473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release Hydeal-D 0.2% vaginal gel applied every three days for 12 weeks
Number of subjects: 85
Study 34477473 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 85
Study 34477473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release Hydeal-D 0.2% vaginal gel
Number of subjects: 85
Study 34477473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 32729363 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drugs (specific drugs not mentioned)
Number of subjects: 0
Study 32729363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug combination therapy
Number of subjects: 0
Study 35798248 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + AVOID
Number of subjects: 500
Study 35798248 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + RESIST
Number of subjects: 500
Study 35798248 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + AVOID + RESIST
Number of subjects: 500
Study 35798248 — intervention group
Group type: COMPARATOR
Intervention: WW alone
Number of subjects: 500
Study 34637408 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 128
Study 34637408 — intervention group
Group type: COMPARATOR
Intervention: Standardized nonoperative care
Number of subjects: 128
Study 34977961 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sprint training under hypoxia (RSH, FIO2=14.5%)
Number of subjects: 14
Study 34977961 — intervention group
Group type: COMPARATOR
Intervention: Repeated sprint training under normoxia (RSN, FIO2=20.9%)
Number of subjects: 14
Study 34977961 — intervention group
Group type: EXPERIMENTAL
Intervention: RSH
Number of subjects: 14
Study 32802264 — intervention group
Group type: EXPERIMENTAL
Intervention: NSDP plus supragingival irrigation with aerosolized 0.5% hydrogen peroxide (H2O2) solution
Number of subjects: 35
Study 32802264 — intervention group
Group type: COMPARATOR
Intervention: NSDP alone
Number of subjects: 35
Study 35549696 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate (VLP) fixation
Number of subjects: 140
Study 35549696 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 140
Study 34583237 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak wiping pressure (12-14 mmHg)
Number of subjects: 47
Study 34583237 — intervention group
Group type: COMPARATOR
Intervention: Ordinary wiping pressure (23-25 mmHg)
Number of subjects: 47
Study 35436135 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella device
Number of subjects: 0
Study 35606663 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1386
Study 35606663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1386
Study 35606663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1386
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 positive women with negative cytology
Number of subjects: 2300
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 positive women with HSIL+ cytology
Number of subjects: 2300
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 positive women
Number of subjects: 2300
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ASC-H cytology
Number of subjects: 2300
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Women younger than 35 years
Number of subjects: 2300
Study 32484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 65 to 74 years
Number of subjects: 2300
Study 36058838 — intervention group
Group type: EXPERIMENTAL
Intervention: Food addiction
Number of subjects: 249
Study 36058838 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease
Number of subjects: 249
Study 36058838 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric imbalance
Number of subjects: 249
Study 36058838 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated article)
Number of subjects: 249
Study 33578328 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐DACPR with rapid transition
Number of subjects: 131
Study 33578328 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐DACPR with delayed transition
Number of subjects: 131
Study 33578328 — intervention group
Group type: COMPARATOR
Intervention: C‐DACPR
Number of subjects: 131
Study 32302347 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20mg before and during the first cycle of chemotherapy
Number of subjects: 36
Study 32302347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 616379577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA/min) stimulation to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 50
Study 616379577 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 50
Study 35154575 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (400 mg/day) along with DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day) for 8 weeks
Number of subjects: 30
Study 35154575 — intervention group
Group type: COMPARATOR
Intervention: DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day)
Number of subjects: 30
Study 34634721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Number of subjects: 18501
Study 34634721 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 18501
Study 32618122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin at 20 mg/kg per day
Number of subjects: 49
Study 32618122 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus opioid
Number of subjects: 49
Study 34844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT) with 512 impulses of 0.15mJ/mm2, twice per week for 4 weeks
Number of subjects: 40
Study 34844816 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for burn scars
Number of subjects: 40
Study 32845997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-Acetylcysteine (NAC)
Number of subjects: 102
Study 32845997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 35925970 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized maternal meal
Number of subjects: 25
Study 35925970 — intervention group
Group type: COMPARATOR
Intervention: Extended fast
Number of subjects: 25
Study 35925970 — intervention group
Group type: COMPARATOR
Intervention: Standardized maternal meal vs Extended fast
Number of subjects: 25
Study 34726542 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous Telepsychiatry (ATP)
Number of subjects: 645
Study 34726542 — intervention group
Group type: COMPARATOR
Intervention: Synchronous Telepsychiatry (STP)
Number of subjects: 645
Study 32302709 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED (Crohn's Disease Exclusion Diet) with 50% enteral nutrition (n = 39)
Number of subjects: 73
Study 32302709 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive enteral nutrition (EEN) (n = 34)
Number of subjects: 73
Study 32302709 — intervention group
Group type: COMPARATOR
Intervention: CDED and EEN
Number of subjects: 73
Study 35489100 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aerobic exercise (5 days/week, 20 min/day at individualized intensity [80% HR at exercise test cessation])
Number of subjects: 16
Study 35489100 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (no exercise recommendations)
Number of subjects: 16
Study 34978552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized concentrate of purple corn (Zea mays L.) 200 mg
Number of subjects: 112
Study 34978552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 36125974 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT) + Stretching Exercises (SEs)
Number of subjects: 69
Study 36125974 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston Technique® (GT®) + Stretching Exercises (SEs)
Number of subjects: 69
Study 36125974 — intervention group
Group type: COMPARATOR
Intervention: Stretching Exercises (SEs) (Control Group)
Number of subjects: 69
Study 34112947 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33374687 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection
Number of subjects: 60
Study 33374687 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS) injection
Number of subjects: 60
Study 33374687 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LD) injection
Number of subjects: 60
Study 33256462 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from low-income households
Number of subjects: 0
Study 33256462 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller family size, greater food diversity, and good farming practices
Number of subjects: 0
Study 33256462 — intervention group
Group type: EXPERIMENTAL
Intervention: Households living under severe levels of poverty
Number of subjects: 0
Study 33443879 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional simulation
Number of subjects: 25
Study 33443879 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual outcomes
Number of subjects: 25
Study 33443879 — intervention group
Group type: COMPARATOR
Intervention: Preoperative images
Number of subjects: 25
Study 33443879 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment nasofrontal angle
Number of subjects: 25
Study 33443879 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment nasolabial angle
Number of subjects: 25
Study 33443879 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual dosage
Number of subjects: 25
Study 32503005 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification program
Number of subjects: 68
Study 32503005 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (control)
Number of subjects: 68
Study 32503005 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole population (≥5% weight loss at 12 months)
Number of subjects: 68
Study 33838534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FIO2 group (intraoperative: FIO2 0.35, during induction and recovery: FIO2 0.7)
Number of subjects: 190
Study 33838534 — intervention group
Group type: COMPARATOR
Intervention: Conventional FIO2 group (intraoperative: FIO2 0.6, during induction and recovery: FIO2 1.0)
Number of subjects: 190
Study 33501814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation environment
Number of subjects: 15
Study 33501814 — intervention group
Group type: COMPARATOR
Intervention: Medium-fidelity simulation scenario
Number of subjects: 15
Study 33501814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high-fidelity and medium-fidelity)
Number of subjects: 15
Study 34371515 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS (nonmedical switching group)
Number of subjects: 54
Study 34371515 — intervention group
Group type: COMPARATOR
Intervention: Continuous MMF treatment (control group)
Number of subjects: 54
Study 33956981 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-informed attention model integrated into BioBERT
Number of subjects: 0
Study 33956981 — intervention group
Group type: COMPARATOR
Intervention: BioBERT without MD-informed attention
Number of subjects: 0
Study 32848381 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 775
Study 32848381 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 775
Study 32848381 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 775
Study 32848381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study 34230959 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-MiHealth digital tool for screening
Number of subjects: 15780
Study 34230959 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 15780
Study 32234313 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based intervention
Number of subjects: 3414
Study 32234313 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 3414
Study 35322857 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback training
Number of subjects: 104
Study 35322857 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 32386811 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 54
Study 32386811 — intervention group
Group type: COMPARATOR
Intervention: UT‐DSAEK
Number of subjects: 54
Study 33666188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine 1.5% ophthalmic drops
Number of subjects: 50
Study 33666188 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic drops
Number of subjects: 50
Study 33666188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study 33666188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory findings of absolute eosinophil count
Number of subjects: 50
Study 33549312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (oral levofloxacin 500 mg and tinidazole 1,000 mg daily for 14 days)
Number of subjects: 132
Study 33549312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 132
Study 33549312 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm (attempted pregnancy)
Number of subjects: 132
Study 33549312 — intervention group
Group type: COMPARATOR
Intervention: Control arm (attempted pregnancy)
Number of subjects: 132
Study 33549312 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm (randomized subjects)
Number of subjects: 132
Study 33549312 — intervention group
Group type: COMPARATOR
Intervention: Control arm (randomized subjects)
Number of subjects: 132
Study 32379675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Empathy Training (MBET)
Number of subjects: 123
Study 32379675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 34627753 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Assisted Advance Care Planning (ACP) intervention
Number of subjects: 923
Study 34627753 — intervention group
Group type: COMPARATOR
Intervention: Usual ACP practices (Control)
Number of subjects: 923
Study 33639839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg ABW
Number of subjects: 188
Study 33639839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg IBW
Number of subjects: 188
Study 33639839 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 5 mg and glycopyrrolate 1 mg
Number of subjects: 188
Study 33639839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg ABW
Number of subjects: 188
Study 33639839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg IBW
Number of subjects: 188